No connection

Search Results

ZYBT

BEARISH
$0.92 Live
Zhengye Biotechnology Holding Limited · NASDAQ
$0.68 52W Range $14.3

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 24, 2026
Market cap
$43.6M
P/E
N/A
ROE
-6.4%
Profit margin
-12.6%
Debt/Equity
0.23
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
90%
ZYBT presents a high-risk profile characterized by a catastrophic price collapse and severe revenue contraction. While the Piotroski F-Score of 5/9 suggests stable internal financial health and the low Debt/Equity ratio (0.23) indicates minimal leverage, these are overshadowed by a -34.40% YoY revenue decline and negative operating margins. The stock is currently trading near its 52-week low after a massive 88.2% one-year decline, signaling a complete loss of investor confidence. Despite a low Price/Sales ratio of 0.28, the lack of growth and profitability makes the current valuation a value trap.

Key Strengths

Stable Piotroski F-Score (5/9)
Low Debt/Equity ratio (0.23)
Healthy Current Ratio (1.49)
Positive Gross Margin (37.37%)
Trading near book value (P/B 1.01)

Key Risks

Severe revenue contraction (-34.40% YoY)
Deeply negative operating margins (-46.33%)
Catastrophic price performance (-88.2% 1Y)
Micro-cap liquidity risk ($0.04B Market Cap)
Complete lack of analyst coverage and target pricing
AI Fair Value Estimate
Based on comprehensive analysis
$0.85
-7.6% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
24
Weak
Value
45
Future
10
Past
5
Health
60
Dividend
0
AI Verdict
High Risk / Value Trap
Key drivers: Revenue collapse, Price crash, Negative profitability
Confidence
90%
Value
45/100

P/S is extremely low, but Graham Number is unavailable due to lack of earnings.

Positives
  • Very low P/S ratio (0.28)
  • P/B near 1.0
Watchpoints
  • No earnings to support P/E
  • Value is eroding due to negative growth
Future
10/100

Growth metrics are severely distressed.

Positives
No standout positives identified.
Watchpoints
  • Revenue growth is -34.40%
  • Operating margins are deeply negative
Past
5/100

Long-term and short-term price trends are aggressively bearish.

Positives
No standout positives identified.
Watchpoints
  • 1Y return of -88.2%
  • 5Y return of -81.1%
Health
60/100

Balance sheet is the only stable component; Piotroski score is the primary positive driver.

Positives
  • Piotroski F-Score 5/9
  • Low leverage (D/E 0.23)
  • Current Ratio 1.49
Watchpoints
  • Negative ROE and ROA
Dividend
0/100

Non-dividend paying company.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.92

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for ZYBT and closest competitors.

Updated 2026-04-23
ZYB
Zhengye Biotechnology Holding Limited
Primary
5Y
-81.1%
3Y
-81.1%
1Y
-88.2%
6M
-63.5%
1M
+5.8%
1W
-10.7%
RLY
Rallybio Corporation
Peer
5Y
-92.7%
3Y
-76.3%
1Y
+311.0%
6M
+92.1%
1M
-12.2%
1W
-2.6%
ARA
Accuray Incorporated
Peer
5Y
-93.2%
3Y
-87.0%
1Y
-78.7%
6M
-76.4%
1M
-27.4%
1W
-24.4%
APL
Apollomics, Inc.
Peer
5Y
-98.0%
3Y
-98.1%
1Y
+148.8%
6M
+191.4%
1M
-0.5%
1W
-0.8%
RNX
RenovoRx, Inc.
Peer
5Y
-86.2%
3Y
-68.2%
1Y
-2.0%
6M
-10.7%
1M
-2.9%
1W
+1.5%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
1.01
P/S Ratio
0.28
EV/Revenue
0.96
EV/EBITDA
-66.84
Market Cap
$43.6M

Profitability

Profit margins and return metrics

Profit Margin -12.6%
Operating Margin -46.33%
Gross Margin 37.37%
ROE -6.38%
ROA -3.45%

Growth

Revenue and earnings growth rates

Revenue Growth -34.4%
Earnings Growth N/A
Q/Q Revenue Growth N/A
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.23
Low debt
Current Ratio
1.49
Good
Quick Ratio
1.0
Good
Cash/Share
$1.0

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q2 2025

Total Assets
$0.5B
Liabilities
$0.1B
Equity
$0.3B
Debt/Equity
0.47x

Healthcare Sector Comparison

Comparing ZYBT against 548 companies in the Healthcare sector (30 bullish, 163 neutral, 355 bearish)
Return on Equity (ROE)
-6.38%
This Stock
vs
-89.9%
Sector Avg
-92.9% (Below Avg)
Profit Margin
-12.6%
This Stock
vs
-16.4%
Sector Avg
-23.2% (Weaker)
Debt to Equity
0.23
This Stock
vs
2.71
Sector Avg
-91.3% (Less Debt)
Revenue Growth
-34.4%
This Stock
vs
126.74%
Sector Avg
-127.1% (Slower)
Current Ratio
1.49
This Stock
vs
4.53
Sector Avg
-67.0% (Weaker)

Similar Companies

Peer comparison within the same industry

SEC Filings

Recent regulatory filings from the SEC EDGAR database

20-F
ANNUAL REPORT
2025-07-03

ZYBT filed its annual report on Form 20-F on July 3, 2025. Due to the limited information provided, specific financial highlights and risk factors are unavailable for summary.

Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning ZYBT from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI Chat
Markets
Profile